Valuation: Wockhardt Limited

Market Cap 339B 3.52B 3.13B 2.92B 2.66B 5.02B 5.07B 35.35B 13.7B 173B 13.22B 12.94B 556B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 354B 3.68B 3.27B 3.05B 2.78B 5.25B 5.3B 36.97B 14.33B 181B 13.83B 13.53B 581B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-1.53%
1 week-8.02%
Current month-1.53%
1 month+9.43%
3 months+6.87%
6 months+63.89%
Current year+44.09%
1 week 2,035.6
Extreme 2035.6
2,267
1 month 1,967.3
Extreme 1967.3
2,360
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-8.02%+39.60%+785.82% 3.52B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.36%-3.94%+28.42%+130.02% 370.07B
Weighted average by Cap. +0.42%-3.33%+30.53%+69.64%

Financials

2025 2026
Net sales 30.35B 316M 281M 262M 239M 450M 454M 3.17B 1.23B 15.52B 1.19B 1.16B 49.79B 34.62B 360M 320M 299M 272M 513M 518M 3.61B 1.4B 17.7B 1.35B 1.32B 56.8B
Net income -470M -4.89M -4.34M -4.05M -3.7M -6.97M -7.03M -49.06M -19.01M -240M -18.36M -17.96M -771M 2.13B 22.16M 19.69M 18.37M 16.75M 31.59M 31.88M 222M 86.16M 1.09B 83.19M 81.38M 3.49B
Net Debt 14.33B 149M 132M 124M 113M 212M 214M 1.5B 580M 7.33B 560M 548M 23.51B 15.53B 162M 144M 134M 122M 230M 232M 1.62B 628M 7.94B 607M 593M 25.48B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-10-01 ₹2,083.90 -1.53% 784,540
26-09-30 ₹2,116.30 -3.55% 823,461
26-09-29 ₹2,194.20 +0.30% 1,274,737
26-09-28 ₹2,187.60 -3.44% 649,952
26-09-25 ₹2,265.60 -0.97% 689,934
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock